Good Morning America: New Study Highlights Benefits to Weight Loss Drugs

Dr. Mikhail Kosiborod, cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, was the lead author of the STEP-HFpEF trial.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

The study and its results were highlighted on Good Morning America.

Dr. Kosiborod presented the findings during the opening late breaking clinical trial session at the European Society of Cardiology Congress—the world’s largest cardiology conference— in Amsterdam, Netherlands. The results have been published in the New England Journal of Medicine at the time of the presentation.